A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary) ; Rilotumumab (Primary)
- Indications Mesothelioma
- Focus Biomarker; Therapeutic Use
- 21 Apr 2011 Amgen has discontinued development of rilotumumab; however, the status of this trial is not clear.
- 19 Apr 2010 New trial record